Ultrasensitive next-generation sequencing-based clonality assay for disease monitoring in B-cell acute lymphoblastic leukaemia2026-07-07T11:50:22-07:00February 20th, 2026|Read more
Measurable Residual Disease detection in acute lymphoblastic leukaemia – comparison between targeted NGS and ASO-qPCR2026-07-09T17:00:41-07:00January 23rd, 2026|Read more
Measurable residual disease monitoring after hematopoietic stem cell transplantation2026-07-06T16:26:02-07:00December 30th, 2025|Read more
Measurable residual mutated NPM1 before allogeneic transplant for acute myeloid leukemia2025-11-24T09:51:38-08:00November 24th, 2025|Read more
QuANTUM-First: Clinical Validation of the LeukoStrat Companion Diagnostic for the Selection of Patients With Acute Myeloid Leukemia Harboring FMS-Like Tyrosine Kinase 3–Internal Tandem Duplications for Treatment With Quizartinib2026-04-20T09:03:35-07:00September 3rd, 2025|Read more
Invivoscribe Launches LeukoStrat KMT2A + MRD Assay to Advance High-Sensitivity Leukemia Testing in Clinical Trials and Patient Management Worldwide2026-10-06T14:42:59-07:00February 4th, 2026|Read more
Invivoscribe Expands Flow Cytometry Services to Accelerate CAR-T Immunotherapy Development and Regulatory Readiness with the Initiation of CERo Therapeutics Phase 1 Clinical Trial2026-03-09T18:04:28-07:00July 7th, 2025|Read more
LabPMM Receives New York State Approval for the NPM1 MRD Assay – Informing Therapy and Accelerating Targeted Trials2026-03-09T18:40:09-07:00June 17th, 2025|Read more
Invivoscribe’s LabPMM Gains New York State Approval for the FLT3 ITD MRD Assay2026-03-09T18:44:44-07:00April 22nd, 2025|Read more
Invivoscribe Announces Registration of the LeukoStrat® CDx FLT3 Mutation Assay in the United Kingdom and Switzerland2026-03-09T18:48:48-07:00March 27th, 2025|Read more
The 66th Annual Meeting of the Japanese Society of Lymphoma Research Jun 4 – 6, 2026 Tokyo, Japan Attending
